High Grade Glioma

In addition, miR-216b expression correlated with increased sensitivity to the CDK4/6 inhibitor Abemaciclib...The observed results support the potential of miR-216b as both a prognostic and predictive indicator in HGGs. The online version contains supplementary material available at 10.1186/s40478-025-02215-5.

MiR-124-3p functions as a tumor suppressor in glioma by repressing STAT3/NAMPT-mediated AKT/ERK signaling, highlighting its potential as a diagnostic biomarker and therapeutic target for glioma management.

P2, N=350, Active, not recruiting, Actuate Therapeutics Inc. | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jun 2026

Stereotactic biopsy of diffuse brainstem tumors can be performed safely. Identification of targets for personalized therapy may be essential for management of these patients.

We demonstrate that our model can predict a spheroid's long-term invasive fate with high accuracy using only partial image sets from early time-points, rather than the complete time-course images. Our work presents an in vivo -like, scalable 3D platform integrated with a quantitative high-throughput pipeline to elucidate GBM invasion mechanisms and to evaluate anti-invasive compounds.

These mechanistic effects translated into a survival benefit in oligodendroglioma xenograft-bearing mice. Together, these findings suggest that IDH1-mutant oligodendroglioma harbors a pre-existing heightened sensitivity to ceramide stress and identify acid ceramidase as a therapeutically actionable target in this disease.

Notably, heterozygosity of Nf1 within the tumor microenvironment does not cause marked changes in the immune tumor microenvironment, gene expression, or differentiation states of neoplastic cells. These data indicate that allografted HGG lines from NPcis mice are an effective model of NF1-HGG, mimicking the complexity observed in human HGG, that can be used for larger scale in vivo drug screening and evaluation.

P4, N=100, Recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2030 --> Dec 2032 | Trial primary completion date: Dec 2029 --> Dec 2032

P=N/A, N=41, Completed, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria

P1/2, N=25, Recruiting, Universita Degli Studi Di Milano Bicocca | Not yet recruiting --> Recruiting

P1, N=36, Suspended, City of Hope Medical Center | Recruiting --> Suspended

Our results revealed that synchronized expression of 5-HTR4 and PDE4D proteins represents a stable modulatory signaling axis of glial-tumor biology, and reflects the activity of cAMP signaling pathway, but cannot independently stratify patients. Moreover, our study confirms that the combination of MIN, CIN and total GI represents a powerful tool for biological tumor stratification, risk assessment and understanding the pathobiological spectrum of the disease.